DIVERSITY:What are the potential regulatory challenges associated with approving new antimicrobial agents targeting Bi(III)-bound NDM-1?

{
  "winner": 2,
  "reasoning": "MS is better because it offers a more multi-faceted perspective by mentioning multiple regulatory challenges such as safety and efficacy demonstration, regulatory standards, resistance management, and complex approval processes. in contrast, NEO focuses mainly on safety, efficacy, and some biochemical considerations, lacking broader regulatory or societal viewpoints, which makes it less diverse overall."
}
